GlassScriptPhysician profile
Lyudmila P Carter
NPI 1285071340
$1,743.49
in general payments reported to CMS, 2019-2025
19 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $43.29 · 2021: $409 · 2022: $211 · 2023: $211 · 2024: $306 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $309.74 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $273.11 | 2021-2024 | Vraylar |
| Indivior INC. | $267.85 | 2019-2025 | Sublocade |
| Pfizer INC. | $181.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $169.44 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $96.13 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $66.67 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $49.35 | 2022 | |
| Lilly USA, LLC | $48.85 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Orexo US, INC. | $43.45 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.86 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $41.52 | 2022 | |
| Circassia INC. | $32.07 | 2019 | |
| Allergan, INC. | $29.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.71 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $17.92 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.98 | 2024 | Jardiance |
| International Rehabilitative Sciences, INC | $15.00 | 2023 | Rs 4i Plus Sequential Stimulator |
| Abbott Laboratories | $14.25 | 2024 | Eterna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyudmila Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.